Reported about 7 hours ago
Eli Lilly has launched higher doses of its weight-loss drug Zepbound in vials in the U.S., priced at $499, which is $150 less than the injector pen versions. The move aims to boost demand amid competition with Novo Nordisk's Wegovy. In addition, Lilly has reduced prices for its lower doses to $349 and $499. The company hopes these changes will attract more patients and increase sales, which have shown signs of weakness recently.
Source: YAHOO